Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients

AIDS

Volumn 27, Issue 16, 2013, Pages 2541-2549

  Macías, Juan ^a   Camacho, Angela ^b   Von Wichmann, Miguel A ^c   López Cortés, Luis F ^d   Ortega, Enrique ^e   Tural, Cristina ^f   Ríos, Maria J ^g   Merino, Dolores ^h   Téllez, Francisco ⁱ   Márquez, Manuel ^j   Mancebo, María ^a   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h Unit of Infectious Diseases   (Spain)

ⁱ Hospital de la Linea de la Concepcion   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

more..

Author keywords

chronic hepatitis C; liver events; liver fibrosis; mortality

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DIGESTIVE TRACT PARAMETERS; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE;

ADULT; BIOPSY; COHORT STUDIES; COINFECTION; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84885427783     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32836381f3     Document Type: Article

References (27)

1. Pineda JA, García-García JA, Aguilar-Guisado M, Ríos-Villegas MJ, Ruíz-Morales J, Rivero A, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622-630.
2. Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50:1056-1063.
3. Merchante N, Giron-González JA, González-Serrano M, Torre-Cisneros J, Garcia-García JA, Arizcorreta A, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20:49-57.
4. Pineda JA, Aguilar-Guisado M, Rivero A, Giron-González JA, Ruiz-Morales J, Merino D, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009; 49:1274-1282.
5. Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2009; 51:585-594.
6. Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-378.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245-264.
8. Ghany MG, Strader DB, Thomas DL. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
9. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C.Hepatology 2003; 38:1449-1457.
10. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
11. Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47:380-384.
12. Vergara S, Macias J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Serrano M, Merino D. The use of transient elasto-metry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45:969-974.
13. Macías J, Recio E, Vispo E, Rivero A, Lopez-Cortes LF, Rios MJ, et al. Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. J Hepatol 2008; 49:916-922.
14. Recio E, Macías J, Rivero-Juárez A, Tellez F, Merino D, Rios M, et al. Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis. Liver Int 2012; 32:1031-1032.
15. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45:1290-1297.
16. Pineda JA, Recio E, Camacho A, Marcias J, Almodvar C, Gonzales-Serrano M, et al. Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis. J Acquir Immune Defic Syndr 2009; 51:445-449.
17. Merchante N, Rivero-Juárez A, Téllez F, Merino D, Jose Rios-Villegas M, Marquez-Solero M, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology 2012; 56:228-238.
18. Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140:1970-1979.
19. Castera L, Forns X, Alberti A. Noninvasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835-847.
20. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
21. Pencina MJ, D'Agostino RB, D'Agostino RB. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. StatMed 2008; 27:157-172.
22. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, deOca RM, et al. Rapidfibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21:2209-2216.
23. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
24. Jacobson IM, McHutchison JG, Dusheiko G, Di Biscegli AM, Reddy KR, Bzowaj NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
25. Bacon BR, Gordon SC, Lawitz E, Marcelline P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
26. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Robers S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
27. Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterol-ogy 2012; 142:1314-1323.